Targeting our second brain to fight diabetes

The enteric nervous system (ENS) plays a key role in controlling the gut-brain axis under normal and pathological conditions, such as type 2 diabetes (T2D)

The discovery of intestinal actors, such as enterosynes, which are able to modulate the ENS-induced duodenal contraction, opens news research avenues.

Decreasing duodenal contraction is now considered as a major focus for the treatment of type 2 diabetes

Therefore, identifying bioactive molecules able to target the enteric nervous system, which controls the motility of intestinal smooth muscle cells, represents a pioneering therapeutic approach. Thus, we chose to study the impact of oral galanin on the ENS in diabetic mice.

Methods :

Enteric neurotransmission, duodenal contraction, glucose absorption, modification of gut-brain axis, and glucose metabolism (glucose tolerance, insulinemia, glucose entry in tissue, hepatic glucose metabolism) were assessed.

Results :

We show that galanin, a neuropeptide expressed in the small intestine, decreases duodenal contraction by stimulating nitric oxide release from enteric neurons. This is associated with modification of hypothalamic nitric oxide release that favors glucose uptake in metabolic tissues such as skeletal muscle, liver, and adipose tissue. Oral chronic gavage with galanin in diabetic mice increases insulin sensitivity, which is associated with an improvement of several metabolic parameters such as glucose tolerance, fasting blood glucose, and insulin.

Conclusion :

In this study, we demonstrate that oral galanin administration improves glucose homeostasis via the enteric nervous system and could be considered a therapeutic potential for the treatment of T2D.

Source : Abot A, Lucas A, Bautzova T, Bessac A, Fournel A, Le-Gonidec S, Valet P, Moro C, Cani PD, Knauf C. Galanin enhances systemic glucose metabolism through enteric Nitric Oxide Synthase-expressed neurons. Mol Metab. 2018 Apr;10:100-108. doi: 10.1016/j.molmet.2018.01.020. Epub 2018 Jan 31. PMID: 29428595; PMCID: PMC5985240.




Enterosys welcomes its new assistant engineer

Manon Carratala Lasserre joined the Enterosys team in November 2022 and is in charge of service delivery. She obtained a Master’s degree in Immunology and infectious diseases at the Paul Sabatier University in Toulouse. During her internships, she first worked on...

Enterosys participates in Biofit 2022 in Strasbourg

With the highest attending rate of academics, TTOs and research institutions, BioFIT is the place where academia-industry collaborations get started. BioFIT has taken on a whole new dimension becoming the meeting point in Europe for tech transfer and for sourcing...

Enterosys will attend NutrEvent 2022 in Nantes

NutrEvent is the event dedicated to innovation in Food, Feed, Nutrition and Health. This year, NutrEvent is back for its 8th edition in a hybrid format. This hybrid event will be held both in-person and online. Enterosys will be present with a validated, complete and...

Enterosys welcomes its new business developer

This month, Pauline Caseilles joined the Enterosys team as a Scientific Business Developer. Her mission: to publicize Enterosys' service offerings. Pauline obtained a Master’s degree in Health Biology and a Specialized Mastere in Marketing and Sales also in the field...

Antioxidant and anti-inflammatory properties of maternal milk

The high hydrostatic pressure processing of donor milk may better protect preterm infants from gut and liver pathologies compared to Holder pasteurization, which is currently used in most human milk banks Preterm infants are highly susceptible to oxidative stress due...